Thrombolytic Agents: Nanocarriers in Targeted Release
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.)...
Guardado en:
Autores principales: | Minghua Shen, Yujiao Wang, Fan Hu, Linwen Lv, Kui Chen, Gengmei Xing |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature
por: Shiqi Guo, et al.
Publicado: (2021) -
Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies
por: Alkaff SA, et al.
Publicado: (2020) -
Extracellular Vesicles – Advanced Nanocarriers in Cancer Therapy: Progress and Achievements
por: Huyan T, et al.
Publicado: (2020) -
Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective
por: Zhang J, et al.
Publicado: (2021) -
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova E, et al.
Publicado: (2019)